Alpha-1 Antitrypsin Deficiency in Patients With Cirrhosis in a US National Cohort
Authors:
- Binu V. JohnBJBinu V. John
- Dustin BastaichDBDustin Bastaich
- Andres SamosASAndres Samos
- Austen HentschelAHAusten Hentschel
- Sunny SandhuSSSunny Sandhu
- Raphaella D. FerreiraRFRaphaella D. Ferreira
- Tamar TaddeiTTTamar Taddei
- Brian GarnetBGBrian Garnet
- David E. KaplanDKDavid E. Kaplan
- Michael CamposMCMichael Campos
- Bassam DahmanBDBassam Dahman
- 16 February 2026
- journal article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (4) , e00995
Abstract
INTRODUCTION: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that increases susceptibility to chronic lung and liver diseases. There are limited data on testing rates in patients with cirrhosis. Guidelines recommend AATD testing in cryptogenic liver disease but not in patients with an established etiology. We aimed to quantify AATD testing patterns in a national cohort of patients with cirrhosis to inform guidelines. METHODS: In this retrospective cohort study of veterans with a new diagnosis of cirrhosis between January 1, 2008 and January 31, 2020, with follow-up until February 23, 2023, we identified predictors of testing, and of severe AATD (alpha-1 antitrypsin [AAT] < 57 mg/dL or PiSZ/PiZZ phenotype/genotype). RESULTS: Of the 126,210 patients with cirrhosis, 42,403 (33.6%) were tested, including 38,189 (30.3%) for AAT levels only, 1,103 (0.8%) for genotype/phenotype only, and 3,011 (2.4%) for both. Factors associated with higher AATD testing included specialist evaluation and White race, whereas patients with chronic obstructive pulmonary disease, hepatitis B/C, hepatocellular carcinoma, and hepatic decompensation were less likely to be tested. Only half of the patients with AAT levels of <57 mg/dL underwent genotype/phenotype testing. Most patients (94.7%) with severe AATD-associated liver disease also had an alternate etiology of liver disease, including metabolic dysfunction associated with steatotic liver disease (53.6%) or viral hepatitis (16.1%), and would be missed if testing only patients with cryptogenic liver disease. DISCUSSION: AATD testing rates in veterans with cirrhosis are low, and patients at high-risk are less likely to be tested. Guidelines are needed to emphasize universal AATD testing in patients with cirrhosis regardless of the presence of other risk factors.Keywords
This publication has 22 references indexed in Scilit:
- EASL Clinical Practice Guidelines on genetic cholestatic liver diseasesJournal of Hepatology, 2024
- Hepatitis delta testing trends in a US national cohort: An analysis of patient and provider-level predictive factorsHepatology Communications, 2024
- Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With CirrhosisClinical Gastroenterology and Hepatology, 2023
- Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascitesHepatology, 2023
- Optimal alpha-1 antitrypsin level cutoffs for genotype identification in patients with chronic liver diseaseHepatology Communications, 2023
- Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosisJournal of Hepatology, 2022
- Fazirsiran for Liver Disease Associated with Alpha 1 -Antitrypsin DeficiencyNew England Journal of Medicine, 2022
- Alpha1-Antitrypsin DeficiencyNew England Journal of Medicine, 2020
- Cutoff level to detect heterozygous alpha 1 antitrypsin deficiency in Turkish populationJournal of Clinical Laboratory Analysis, 2011
- Chronic liver disease in heterozygous α1-antitrypsin deficiency PiZJournal of Hepatology, 2000